Kbi-092 File

The trial focuses on patients with relapsed/refractory AML, especially those with specific mutations like FLT3 , U2AF1 , or SF3B1 , which are known to drive IRAK4 activity. Pharmaceutical Manufacturing & Development

Mutations in the FLT3 gene are among the most common genetic alterations in AML. These mutations cause the FLT3 receptor to stay "on" permanently, sending constant growth and survival signals to leukemia cells.

As of late 2025, KBI-092 has moved into the active clinical testing phase: KBI-092

They provide the necessary infrastructure—including mammalian and microbial expression systems —to ensure that experimental compounds like KBI-092 meet strict GMP (Good Manufacturing Practice) standards for human testing. Description Primary Code Drug Class Small molecule antineoplastic; Dual Kinase Inhibitor Targets FLT3 and IRAK4 Primary Indication Relapsed/Refractory Acute Myeloid Leukemia (RR-AML) Administration Oral tablet, twice daily (BID) Trial Phase Phase 1 (First-in-Human)

Developed primarily by , KBI-092 (HPB-092) is a novel dual-kinase inhibitor designed to disrupt survival signals that allow cancer cells to resist standard treatments. The Mechanism of Action: Dual Inhibition The trial focuses on patients with relapsed/refractory AML,

The drug has received clearance from both the FDA (United States) and the NMPA (China) to begin Phase 1 clinical trials.

The ongoing research into KBI-092 represents a shift toward more sophisticated, multi-targeted therapies that address the inherent complexity and adaptability of blood cancers. HPB 092 - AdisInsight As of late 2025, KBI-092 has moved into

This protein is a central mediator in the toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways. These pathways are frequently hijacked by cancer cells to promote inflammation and evade cell death, particularly in patients who have failed prior FLT3 inhibitor therapy.